| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.9 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |